The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia I

The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia in the Intensive Care Unit

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06005454

Enrollment

122

Registered

2023-08-22

Start date

2023-09-01

Completion date

2024-10-11

Last updated

2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

The aim of study is to investigate the effect of enteral feeding of Omega-3 on the outcome of children with Pneumonia in PICU

Detailed description

Group A(cases) will be supplemented by omega-3 fatty acids for immediate post admission consecutive 7 days besides conventional treatment of pneumonia, in a dose of 350 mg twice daily for children less than 3 years and 450 mg twice daily for older children according to the standard treatment per the American Institute of Medicine of the National Academies guidelines for maximum dose for this age group. (Institute of Medicine of the National Academies,2016) Side effects of omega-3 supplements are usually mild. They include unpleasant taste, bad breath, bad-smelling sweat, headache, and gastrointestinal symptoms such as heartburn, nausea, and diarrhea. (Office of Dietary Supplements ,2016) Group B(controls) will be received enteral feeding without omega-3 fatty acid support.

Interventions

DIETARY_SUPPLEMENTFish oil (Omega)

We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Investigator)

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender

ALL

Age

1 Months to 5 Years

Healthy volunteers

Yes

Inclusion criteria

* All children patients with severe pneumonia admitted to PICU * Both sexes * Age: under 5 years * Whose parents or caregivers approve for participation in the study

Exclusion criteria

* Patients with chronic illnesses to exclude bias that could be emerged due to the chronic disease effect * Whose parents or caregivers will not apply for participation in the study * Patients who will be contraindicated for enteral feeding

Design outcomes

Primary

Measure	Time frame	Description
Hospital length stay	Through study completion, an average of 1 yea	Hospital length stay will be measured between the two groups

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026